VERIGRAFT appointed as industry representative on Sweden’s national forum for advanced therapies.
CEO Petter Björquist to lead alongside partners AstraZeneca, Cytiva, Sweden Bio and CCRM Nordic. The board, comprising seven key organizations, will guide Sweden’s push to become a leader in the rapidly growing field of Advanced Therapy Medicinal Products (ATMP). Selection made in consultation with industry stakeholders Läkemedelsindustriföreningen (Lif) and Sweden Bio, reinforcing a collaborative vision for advancing Sweden’s position in this dynamic sector.
CEO Petter Björquist expresses, “We are very proud to have received this nomination, and we look forward to contributing to Sweden’s leadership in the evolving landscape of advanced therapies.”
